Elias Kassab, MD
Cardiovascular Disease · Dearborn, MINPI 1922076835
Payments from drug & device makers
What this record shows
This record is dominated by grants: $110,000 of the $172,243 with a category attached, or 63.9%. Catheter Precision, Inc. FKA Ra Medical Systems, Inc. accounts for 71.9% of it on its own, with 57 other manufacturers making up the rest. Reporting peaked in 2019 at $145,626 and has fallen 98.4% since, to $2,326 in 2025. Among cardiovascular disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 953 payments — averaging $180.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Catheter Precision, Inc. FKA Ra Medical Systems, Inc.$124K
- E.r. Squibb & Sons, L.L.C.$9K
- Amgen$8K
- Bard Peripheral Vascular, Inc.$7K
- Cardiovascular Systems Inc.$3K
- Philips North America LLC$3K
- plus $18K from 52 others
Across 32 payments — averaging $7471.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$108K
- Cardiovascular Systems Inc.$59K
- Vesper Medical$33K
- Trireme Medical LLC$12K
- Currax Pharmaceuticals LLC$9K
- Bayer$8K
- plus $10K from 4 others
What the payments were for
- Consulting fees$19,50011%
- Speaking & faculty fees$22,12513%
- Grants$110,00064%
- Travel & lodging$4810%
- Food & beverage$19,21111%
- Education$9261%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DABRA$123,500
- ELIQUIS$8,550
- Repatha$6,850
- Abre$2,800
- Spectranetics Undiv$2,500
- Diamondback Peripheral$1,800
- Auryon$667
- IGT_D Systems$661
- XARELTO$382
- Peripheral Orbital Atherectomy System$338
- LifeVest$256
- Auryon Laser System 100-120 Vac$234
- VENOVO$126
- WAINUA$125
- Edarbyclor$111
- Coronary Orbital Atherectomy System$110
- Flexitouch Plus$110
- ENTRE$110
- Xience Sierra Coronary Stent System$110
- Saxenda$102
How this compares
$172,243 in reported general payments places this provider in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 276 | $350,157 |
| EntrestoSacubitril/Valsartan | 134 | $176,256 |
| XareltoRivaroxaban | 139 | $158,272 |
| JardianceEmpagliflozin | 132 | $146,869 |
| Repatha SureclickEvolocumab | 94 | $114,170 |
| BrilintaTicagrelor | 117 | $91,132 |
| CamzyosMavacamten | 11 | $88,857 |
| Praluent PenAlirocumab | 76 | $56,367 |
| VerquvoVericiguat | 19 | $25,770 |
| NexlizetBempedoic Acid/Ezetimibe | 20 | $20,750 |
| FarxigaDapagliflozin Propanediol | 28 | $20,683 |
| Repatha SyringeEvolocumab | 26 | $19,272 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 27 | $14,397 |
| EdarbiAzilsartan Medoxomil | 21 | $14,002 |
| Metoprolol Succinate | 837 | $13,915 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $343 | $350,157276 claims |
| NovartisEntresto | $838 | $176,256134 claims |
| Johnson & JohnsonXarelto | $1,363 | $158,272139 claims |
| Boehringer IngelheimJardiance | $309 | $146,869132 claims |
| AstraZenecaBrilinta, Farxiga | $782 | $111,814145 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $9,185 | $88,85711 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $309 | $28,40048 claims |
| MerckVerquvo | $798 | $25,77019 claims |
| Esperion Therapeutics, Inc.Nexlizet | $571 | $20,75020 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $571 | $8,51913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Dearborn
- Sohail HassanDearborn$121K
- Marschall RungeAnn Arbor$1.8M
- Jihad MustaphaGrand Rapids$1.6M
- Vallerie McLaughlinAnn Arbor$947K
- Pedro Villablanca SpinettoDetroit$620K
- Stanley ChetcutiAnn Arbor$573K
- David HainesRoyal Oak$492K
- Steven AlmanyTroy$471K
- David StroblLansing$445K
- Herman KadoSouthfield$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.